The Journal of Infectious Diseases最新文献

{"title":"Invasive Group B Streptococcal Disease Among Nonpregnant Adults: Alaska, 2004–2023","authors":"Victoria A Balta, Sara Bressler, Stephanie Massay, Laurie Orell, Alisa Reasonover, Marcella Harker-Jones, Tony Kretz, Marc Fischer, Joseph McLaughlin, Jonathan Steinberg","doi":"10.1093/infdis/jiaf055","DOIUrl":"https://doi.org/10.1093/infdis/jiaf055","url":null,"abstract":"We describe the epidemiology of invasive group B streptococcal (GBS) disease among nonpregnant Alaska adults using statewide surveillance data. During 2004–2023, 880 cases of invasive GBS disease were reported for an age-adjusted annual incidence of 9.1 (95% confidence interval [CI], 8.5–9.7) cases per 100 000 adults. Incidence increased 1.9-fold (95% CI, 1.6–2.2) between 2004–2013 and 2014–2023. Adults aged ≥65 years had a 4.4-fold higher risk of invasive disease compared to younger adults, and 47% of adults with invasive GBS had diabetes. Health care providers should be aware of populations at increased risk, potentially allowing for more prompt treatment.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143546225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High Epstein-Barr Virus DNA Load in T Cells Predicts Hemophagocytic Lymphohistiocytosis","authors":"Xiaohui Fang, Shanshan Xu, Kang Cai, Xin Cong, Yujia Li, Yan Li, Hongqiang Shen, Xiaojun Xu, Lisu Huang","doi":"10.1093/infdis/jiaf065","DOIUrl":"https://doi.org/10.1093/infdis/jiaf065","url":null,"abstract":"Background To evaluate the risk of hemophagocytic lymphohistiocytosis (HLH) linked to Epstein-Barr virus (EBV) infection in different lymphocyte subtypes during infectious mononucleosis (IM). Methods Patients with IM and patients with EBV-HLH were included within the Children's Critical EBV Infection cohort for a nested case-control study. Lymphocytes were isolated into T, B, and natural killer cells using magnetic bead sorting, followed by individual polymerase chain reaction testing. Receiver operating characteristic curve analysis identified subtype-specific cutoffs for EBV-HLH prediction. Kaplan-Meier and Cox regression analyses assessed viral load-HLH risk associations. Results Patients with EBV-HLH exhibited significantly higher T-cell viral loads than patients with IM (median, 5.1 × 104 vs 6.0 × 102 copies/106 cells). A T-cell viral load >1.5 × 104 copies/106 cells was linked with higher incidences of viral sepsis, renal dysfunction, hepatic dysfunction, coagulation dysfunction, and cardiovascular dysfunction (odds ratios, 10.0, 4.7, 6.5, 15.7, and 6.5). This elevated T-cell viral load was a strong predictor for distinguishing EBV-HLH (AUC 0.815) and increased the risk of developing EBV-HLH (hazard ratio 4.7). Conclusions High EBV DNA load in T cells can serve as a potential predictor for the development of EBV-HLH.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"49 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143546162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Testosterone Therapy on the Vaginal Microbiota of Transgender Men and Non-Binary People: A Prospective Study","authors":"Olivia T Van Gerwen, Kristal J Aaron, Emma Sophia Kay, Krishmita Siwakoti, Angela Pontius, Saralyn Richter, Z Alex Sherman, Keonte J Graves, Ashutosh Tamhane, Jacob H Elnaggar, Meng Luo, Evelyn Toh, David E Nelson, Nicholas J Van Wagoner, Christopher M Taylor, Christina A Muzny","doi":"10.1093/infdis/jiaf114","DOIUrl":"https://doi.org/10.1093/infdis/jiaf114","url":null,"abstract":"Background Understanding the impact of testosterone on the vaginal microbiota of transgender men (TGM) and non-binary people assigned female sex at birth over time is imperative as vaginal dysbiosis and incident bacterial vaginosis (iBV) may cause bothersome genital symptoms and increase HIV/STI acquisition risk. We investigated shifts in the composition of the vaginal microbiota over time in TGM initiating testosterone for gender-affirming hormone therapy, including development of vaginal dysbiosis and iBV. Methods Participants ages ≥18 years, assigned female sex at birth and reporting TGM or non-binary identity, interested in starting injectable testosterone, demonstrating optimal vaginal microbiota, with no current STI(s) were enrolled. Participants self-collected daily vaginal specimens for 7 days prior to testosterone initiation and 90 days thereafter for vaginal Gram staining and 16S rRNA gene sequencing. Episodes of vaginal dysbiosis and iBV were defined as Nugent scores ≥4 or ≥7, respectively, each for ≥2 consecutive days. Results Between February 2022-November 2023, 9 participants enrolled, 89% (8/9) developed ≥1 episode(s) of vaginal dysbiosis after testosterone initiation, and 56% (5/9) developed iBV. Among those who developed iBV, most did so between days 20-40 after testosterone initiation. Community state type (CST) I was found most often in participants who did not develop iBV and CST IV-B most often in participants who developed iBV. Sexual activity and menses also appeared to influence the development of iBV. Conclusion The majority of participants developed vaginal dysbiosis including iBV.. Additional studies with larger sample sizes are needed to further elucidate how testosterone impacts the vaginal microbiota.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"37 1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143546223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased cerebrospinal fluid ACE2 fragments as a read-out of brain infection in COVID-19 encephalopathy patients","authors":"Matthew P Lennol, María-Salud García-Ayllón, Carlos Avilés-Granados, Chiara Trasciatti, Chiara Tolassi, Virginia Quaresima, Davide Arici, Viviana Cristillo, Irene Volonghi, Francesca Caprioli, Valeria De Giuli, Sara Mariotto, Sergio Ferrari, Gianluigi Zanusso, Nicholas J Ashton, Henrik Zetterberg, Kaj Blennow, Alessandro Padovani, Andrea Pilotto, Javier Sáez-Valero","doi":"10.1093/infdis/jiaf093","DOIUrl":"https://doi.org/10.1093/infdis/jiaf093","url":null,"abstract":"Background This study assesses the cerebrospinal fluid (CSF) levels of the viral receptor angiotensin-converting enzyme 2 (ACE2) and of the serine protease TMPRSS2 fragments in patients with SARS-CoV-2 infection presenting encephalitis (CoV-Enceph). Methods The study included biobanked CSF from 18 CoV-Enceph, 4 subjects with COVID-19 without encephalitis (CoV), 21 non-COVID-related encephalitis (Enceph), and 21 neurologically healthy controls. Participants underwent a standardized assessment for encephalitis. A large subset of samples underwent an extended panel of CSF neuronal, glial and inflammatory biomarkers. ACE2 and TMPRSS2 species were determined in the CSF by western blotting. Results ACE2 was present in CSF as several species, full-length forms, and two cleaved fragments of 80 and 85 kDa. CoV-Enceph patients displayed increased CSF levels of full-length species, as well as the 80 kDa fragment, but not the alternative 85 kDa fragment, compared with controls and Enceph patients, characterized by increases of both fragments. Furthermore, TMPRSS2 was increased in the CSF of Enceph patients compared with controls, but not in CoV-Enceph patients. The CoV patients without encephalitis displayed unaltered CSF levels of ACE2 and TMPRSS2 species. Conclusions Patients suffering from encephalitis displayed an overall increase in CSF ACE2 probably as a consequence of brain inflammation. The increase of the shortest ACE2 fragment only in CoV-Enceph patients may reflect the enhanced cleavage of the receptor triggered by SARS-CoV-2, thus serving to monitor brain penetrance of the virus associated with the rare encephalitis complication. TMPRSS2 changes in the CSF appeared related with inflammation, but not with SARS-CoV-2 infection.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143546226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Viral and immune factors associated with COVID-19 outcome in the C3PO trial of convalescent plasma","authors":"Clara Di Germanio, Erika G Marques de Menezes, Robert Clevenger, Ian Rines, Valerie L Durkalski-Mauldin, Eric Leifer, Sharon Yeatts, Xutao Deng, Brendan G Balasko, John F McDyer, Leilani Montalvo, Daniel Chafets, Nadine N Talia, Alexandra Weissman, Sumith R Panicker, Yogen Kanthi, Mars Stone, Frederick K Korley, Clifton W Callaway, Philip J Norris","doi":"10.1093/infdis/jiaf109","DOIUrl":"https://doi.org/10.1093/infdis/jiaf109","url":null,"abstract":"We examined innate and antibody responses in C3PO clinical trial participants of COVID-19 convalescent plasma to identify predictors of disease progression. We found SARS-CoV-2 viremia in 64% of participants at enrollment, and we could also quantify viremia in approximately half of those samples using an RT-PCR assay. Viremia was associated with increased risk of disease progression (OR 3.0, 95% CI 1.7–5.0). Participants with viremia at baseline had lower SARS-CoV-2 binding antibody levels and higher pro-inflammatory cytokine levels, including IP-10 (CXCL10), TNF-α, calprotectin, and CRP. Disease progression correlated with extracellular vesicle levels from multiple cell types in the convalescent but not acute phase of the disease. Male sex predicted worse disease outcome and was associated with higher baseline levels of several pro-inflammatory cytokines. Viremia’s strong predictive value for disease progression argues for further study of its use to predict which patients with COVID-19 might require more intensive therapy or monitoring.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"103 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143546219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Omics-Guided Investigation of a Hospital Outbreak Caused by blaNDM-1-Producing Pseudocitrobacter faecalis","authors":"Roberto B M Marano, Yonathan Oster, Shmuel Benenson, Yair Motro, Oshrat Ayalon, Chaggai Rosenbluh, Aline Cuénod, Ayelet Michael-Gayego, Violeta Temper, Jacob Strahilevitz, Jacob Moran-Gilad","doi":"10.1093/infdis/jiaf103","DOIUrl":"https://doi.org/10.1093/infdis/jiaf103","url":null,"abstract":"Carbapenemase-producing Enterobacterales (CPE) pose a major healthcare challenge. We report the first hospital outbreak of Pseudocitrobacter faecalis carrying blaNDM-1 using an omics-based approach. Short- and long-read sequencing enabled genomic epidemiological investigation to track its spread, characterize its resistome, and analyze the genomic context of blaNDM-1. Additionally, we developed and implemented a MALDI-TOF MS-based method for rapid outbreak isolate typing using protein biomarkers. Our investigation identified two independent blaNDM-1-producing clonal clusters of multi-drug and carbapenem-resistant P. faecalis circulating for over three years, carrying blaNDM-1 either chromosomally or on a plasmid. MALDI-TOF MS spectra analysis revealed candidate protein markers corresponding to genomic clusters, with one predicted biomarker applicable for rapid typing. P. faecalis is an emerging CPE taxon requiring hospital surveillance. Early whole genome sequencing (WGS) unexpectedly revealed two intertwined clones with independent carbapenemase acquisition routes. Cluster-specific markers enabled rapid typing, serving as proof-of-concept for validating proteomics in future surveillance.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143546227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Phase 2b Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 6-Valent Group B Streptococcus Vaccine Administered Concomitantly With Tetanus, Diphtheria, and Acellular Pertussis Vaccine in Healthy Nonpregnant Female Individuals","authors":"William B Smith, William Seger, Richard Chawana, Zahra Jefferies, Natalie C Silmon de Monerri, Ye Feng, Michelle Gaylord, Babalwa Jongihlati, Johannes Beeslaar, Julie M Skinner, Kara Bickham, Annaliesa S Anderson","doi":"10.1093/infdis/jiaf096","DOIUrl":"https://doi.org/10.1093/infdis/jiaf096","url":null,"abstract":"Background Maternal group B streptococcus (GBS) infection is associated with substantial risk of preterm birth and infant mortality. Preventative approaches to protect infants from GBS infection are needed. Methods In this phase 2b, randomized study, healthy nonpregnant 18−49-year-old females were randomized 1:1:1 to receive the investigational 6-valent GBS polysaccharide conjugate vaccine (GBS6) and concomitant Tdap (GBS6+Tdap), GBS6 and placebo (GBS6+placebo), or Tdap and placebo (Tdap+placebo). Primary safety endpoints included reactogenicity events within 7 days and adverse events (AEs) through 1 month after vaccination. Primary immunogenicity objectives were to describe immune responses induced by GBS6+Tdap versus Tdap+placebo and versus GBS6+placebo for pertussis, tetanus, and diphtheria Tdap antigens and the 6 GBS6 antigens. Results Overall, 304 participants received study vaccination. Most reactogenicity events were mild or moderate in severity and balanced across vaccine groups. Frequency of AEs was ≤8.1% across vaccine groups. One-month after vaccination, the proportion of participants achieving antibody concentrations ≥0.1 IU/mL, for tetanus and diphtheria antigens was 100% in both GBS6+Tdap and Tdap+placebo groups. Immune responses to pertussis antigens were lower in the GBS6+Tdap group compared to the Tdap+placebo group, with geometric mean ratios <0.6. No consistent effect on immune responses against each of the GBS6 serotypes after concomitant administration with Tdap was observed. Conclusions GBS6 and Tdap administered concomitantly and alone were safe and well tolerated in healthy nonpregnant individuals. Similar immune responses were observed for Tdap when administered with GBS6 or when administered alone. These results will likely inform future studies in pregnant individuals. (NCT04766086).","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143546228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Routine treatment versus selective treatment for individuals reporting contact with sexual partners with chlamydia: A Before-and-After Study","authors":"Danushi Wijekoon, Marcus Y Chen, Yasmin Hughes, Christopher K Fairley, Catriona S Bradshaw, Jason J Ong, Ivette Aguirre, Eric P F Chow","doi":"10.1093/infdis/jiaf107","DOIUrl":"https://doi.org/10.1093/infdis/jiaf107","url":null,"abstract":"Background Many international guidelines recommend routine treatment for individuals reporting sexual contact with sexual partners with chlamydia. In October-2019, the Melbourne Sexual Health Centre changed routine treatment of all chlamydia contacts to selective treatment, reserving same-day treatment for those testing positive, unless patients presented with symptoms or with specific reasons. Methods We conducted a before-and-after study among chlamydia contacts at MSHC by comparing 12 months before the ‘routine treatment period’ (December-2018 to October-2019) and after the ‘selective treatment period’ (November-2019 to December-2020). Results Of the 2843 chlamydia contacts included in the analysis, chlamydia positivity was 31.9% (907/2843). The proportion of contacts who received treatment before test results decreased from 91% (1380/1515) to 56% (739/1328) (p<0.0001). We reviewed 232 of the 739 chlamydia contacts in the selective period to determine reasons for treatment, 41.4% (96/232) were treated due to the presence of symptoms. The proportion of those who received treatment and later tested positive did not change between the two periods (35% [482/1380] vs. 34% [253/739], p=0.750). However, the proportion of contacts who received unnecessary treatment (treated but tested negative) did not change between the two periods (65% [898/1380] vs. 66% [486/739], p=0.750). Of the 60 who did not receive treatment but tested positive subsequently, seven (11.7%) did not return for treatment, and it did not differ between the two periods (p=0.370). Conclusions The selective treatment approach has reduced antibiotic consumption and likely decreased the overall workload of clinic staff by minimising the need to treat all contacts.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"54 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143546631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SLC22A1 resists HBV by activating JAK/STAT pathway and predicts effect of pegIFNα-based therapy on CHB","authors":"Huiying Yu, Bin Li, Huili Guo, Lin Li, Xiaoquan Liu, Lili Wu, Na Gao, Qiyi Zhao, Xiuqing Pang, Zhiliang Gao","doi":"10.1093/infdis/jiaf102","DOIUrl":"https://doi.org/10.1093/infdis/jiaf102","url":null,"abstract":"Background Functional cure is the ideal treatment endpoint of chronic hepatitis B (CHB). Currently, only a few patients achieve this with treatment. Host differences must be influential. Solute Carrier Family 22 Member 1 (SLC22A1), encoding organic cation transporter 1, is expressed in the liver and mediates substance transport of hepatocytes. The association between SLC22A1 and CHB has not been determined. Our objective was to elucidate this association. Methods RNA-seq was performed to explore the changes caused by HBV and SLC22A1. SLC22A1 of plasma and liver biopsies in healthy controls and CHB were measured by ELISA and immunohistochemistry. Plasma from 200 patients with CHB (120 uncured, 80 cured) completing the pegIFNα-based treatment was collected at baseline, 12 and 24 weeks of treatment and measured with ELISA. Results SLC22A1 was downregulated by HBV, as indicated by comparing SLC22A1 of hepG2 and HBV-expression hepG2 cells (hepG2 transfected with pHBV1.3, hepG2.2.15 or hepG2-NTCP infected by HBV) and of both liver and plasma in CHB and healthy volunteers. Plasma SLC22A1 in cured group rose dynamically but not in uncured group. Plasma SLC22A1 at 24 weeks was predictive of functional cure (AUC=0.887) and better when combined with HBsAg at 24 weeks (AUC=0.925). Vitro experiments regarding overexpression of SLC22A1 in hepG2.2.15 demonstrated that HBsAg and HBeAg were inhibited by SLC22A1 through JAK/STAT pathway activation, consistent with transcriptome sequencing results. Conclusions HBV inhibits SLC22A1 expression and SLC22Al suppresses HBV by activating the JAK/STAT pathway. SLC22A1 is a predictor of the functional cure of CHB with pegIFNα-based treatment.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143546493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dolutegravir and Risk of Neuropsychiatric Adverse Events: a Pharmacogenetic Study","authors":"Julien De Greef, Jean Cyr Yombi, Anne Vincent, Bernard Vandercam, Philippe de Timary, Lidvine Boland, Magali Philippeau, Nadtha Panin, Laure Elens, Vincent Haufroid, Leïla Belkhir","doi":"10.1093/infdis/jiaf098","DOIUrl":"https://doi.org/10.1093/infdis/jiaf098","url":null,"abstract":"Dolutegravir treatment can lead to neuropsychiatric adverse events (NPAE). This study assessed the association between NPAE and polymorphisms in dolutegravir-related pharmacogenes, determined by next-generation sequencing panel testing. Using a case-control design, 36 patients having previously discontinued dolutegravir due to NPAE were compared to 98 patients tolerating dolutegravir. In the latter group, psychometric scores were compared according to genotype, targeting polymorphisms associated with drug intolerance. NR1I2 c.-22-7659C>T was independently associated with a reduced risk of NPAE-related dolutegravir discontinuation (odds ratio of 0.36 [95% confidence interval, .15–.88] for T-variant allele carriage) and was linked to decreased anxiety scores in control-group participants.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143546231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}